GlassScriptPhysician profile
William K Naguszewski
NPI 1134103997
$19,253.22
in general payments reported to CMS, 2019-2025
71 companies · $3,832 in 2025
The $3,832 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,109 · 2020: $1,335 · 2021: $2,790 · 2022: $3,060 · 2023: $3,411 · 2024: $3,716 · 2025: $3,832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,431.32 |
| Education | $528.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,031.32 | 2020-2025 | |
| Biogen, INC. | $1,633.78 | 2019-2025 | Tysabri, Vumerity, Tysabri |
| Harmony Biosciences LLC | $1,488.54 | 2020-2025 | Wakix |
| Ucb, INC. | $1,217.21 | 2019-2025 | Briviact, Nayzilam, Zilbrysq |
| Jazz Pharmaceuticals INC. | $1,108.92 | 2020-2025 | |
| Pfizer INC. | $949.97 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $642.06 | 2019-2023 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $605.31 | 2019-2025 | Austedo, Austedo Xr, Austedo Xr |
| Livanova USA, INC. | $572.58 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $478.80 | 2020-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Novartis Pharmaceuticals Corporation | $476.98 | 2019-2025 | |
| Eisai INC. | $460.13 | 2020-2025 | |
| Lundbeck LLC | $416.38 | 2021-2025 | Vyepti |
| Lilly USA, LLC | $411.65 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Neurocrine Biosciences, INC. | $336.34 | 2021-2025 | Ingrezza, Ongentys |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Naguszewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.